Donafenib clinical trials
Includes 6 studies of Donafenib tosylate.
How each study uses donafenib is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the donafenib studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
43 studies that test it; most in 2021 (9)
| Year | Studies |
|---|---|
| 2014 | 2 |
| 2015 | 1 |
| 2016 | 4 |
| 2017 | 1 |
| 2018 | 3 |
| 2019 | 1 |
| 2020 | 2 |
| 2021 | 9 |
| 2022 | 5 |
| 2023 | 1 |
| 2024 | 9 |
| 2025 | 1 |
| 2026 | 4 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 14 · Other 29
Suzhou Zelgen Biopharmaceuticals Co.,Ltd (14) · Fudan University (4) · Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University (3) · Tianjin Medical University Cancer Institute and Hospital (3) · Sun Yat-sen University (2) · Anhui Provincial Hospital (2) · Zhongda Hospital (1) · Second Affiliated Hospital of Guangzhou Medical University (1)
Often tested with
Tested in the same studies.
Sintilimab (7) · Tislelizumab (5) · Toripalimab (3) · Apatinib (2) · Immune checkpoint inhibitors (1) · Lenvatinib (1) · Camrelizumab (1) · Pucotenlimab (1)
Related medicines
As reviewed, each with the page that says it.
- One of Protein Kinase Inhibitors source
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 7
Studies that test donafenib.
- Nov 2026Donafenib Combined With Capecitabine for Postoperative Adjuvant Therapy of Biliary Malignant Tumors With High-risk Recurrence RiskPhase 2 · The First Affiliated Hospital with Nanjing Medical University
- Dec 2026GEMOX Combined With Donafenib and Tislelizumab in Advanced Biliary Tract CarcinomaPhase 2 · Fudan University
- Dec 2026HAIC Combined with Donafenib and Sintilimab As Perioperative Treatment for Resectable Hepatocellular Carcinoma Patients At High Risk of RecurrencePhase 2 · Fudan University
- May 2027Adjuvant Treatment of Patients With High Risk of Recurrent Hepatocellular Carcinoma With Donafenib in Combination With EnvafolimabPhase 2 · Anhui Provincial Hospital
- Jun 2027The DoHAICs Study Expansion PhasePhase 2 · Tianjin Medical University Cancer Institute and Hospital
- Aug 2027Postoperative Adjuvant Therapy of Donafenib for Hepatocellular CarcinomaNot applicable · Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
- Aug 2027FOLFOX-HAIC Combined With Donafenib and Pucotenlimab as First-Line Treatment for Unresectable Intrahepatic CholangiocarcinomaPhase 2 · Sun Yat-sen University
Studies
Open first, then newest update. How each study uses donafenib is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 43
- Epalrestat Combined With HAIC, Donafenib and Tislelizumab as First-line Treatment for Patients With Unresectable HCC and DiabetesRecruitingPhase 2Haibo ShaoNCT07557914Written as Donafenib + Tislelizumab
- A Prospective, Single-Arm, Open-Label Clinical Study of the Efficacy and Safety of Hepatic Arterial Infusion Chemotherapy Combined With Targeted Therapy and a PD-1 Inhibitor in Patients With Postoperative Hepatocellular Carcinoma and Microvascular InvasionNot yet recruitingPhase 4Zhai WenlongNCT07790419Written as Donafenib + lenvatinib+apatinib
- The DoHAICs Study Expansion PhaseNot yet recruitingPhase 2Tianjin Medical University Cancer Institute and HospitalNCT07584018Written as Donafenib
- FOLFOX-HAIC Combined With Donafenib and Pucotenlimab as First-Line Treatment for Unresectable Intrahepatic CholangiocarcinomaNot yet recruitingPhase 2Sun Yat-sen UniversityNCT07353827Written as Donafenib
- GEMOX Combined With Donafenib and Tislelizumab in Advanced Biliary Tract CarcinomaRecruitingPhase 2Fudan UniversityNCT05668884Written as Combination of Gemcitabine, Oxaliplatin, Donafenib and Tislelizumab
- HAIC Combined with Donafenib and Sintilimab As Perioperative Treatment for Resectable Hepatocellular Carcinoma Patients At High Risk of RecurrenceRecruitingPhase 2Fudan UniversityNCT06812039Written as HAIC combined with sintilimab and donafenib
- Donafenib Combined With Capecitabine for Postoperative Adjuvant Therapy of Biliary Malignant Tumors With High-risk Recurrence RiskRecruitingPhase 2The First Affiliated Hospital with Nanjing Medical UniversityNCT06685289Written as Donafenib
- Efficacy of Organoid-Based Drug Screening to Guide Treatment for Locally Advanced Thyroid CancerRecruitingPhase 2West China HospitalNCT06482086Written as Donafenib
- Donafenib as Adjuvant Therapy Following Ablation for Recurrent HCCRecruitingNot applicableSun Yat-sen UniversityNCT06609876Written as Donafenib
- TIPS Plus Half-dose Donafenib in AHCC with PVTT-associated Portal HypertensionRecruitingPhase 2Fei GaoNCT06646198Written as Donafenib
- Postoperative Adjuvant Therapy of Donafenib for Hepatocellular CarcinomaRecruitingNot applicableSun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityNCT06581315Written as Donafenib
- Donafenib Combine With Sintilimab and HAIC in Neoadjuvant of Resectable Hepatocellular CarcinomaNot yet recruitingPhase 2Tianjin Medical University Cancer Institute and HospitalNCT06512467Written as Donafenib
- Adjuvant Treatment of Patients With High Risk of Recurrent Hepatocellular Carcinoma With Donafenib in Combination With EnvafolimabRecruitingPhase 2Anhui Provincial HospitalNCT06498622Written as Donafenib + Envafolimab
- Donafenib Combined With Immunotherapy and Local Therapy for Unresectable Hepatocellular Carcinoma That Has Failed in Previous TherapyNot yet recruitingPhase 4Tongji HospitalNCT06496815Written as Donafenib
- A Study Evaluating the Efficacy and Safety of ZG005 in Combination With Donafenib or Bevacizumab in Patients With Advanced Hepatocellular CarcinomaNot yet recruitingNot applicableChangsha Taihe HospitalNCT06233994Written as Donafenib Tosilate Tablets
- Hepatic Artery Infusion Chemotherapy Plus Donafenib in Patients With Hepatocellular Carcinoma After SurgeryCompletedPhase 2Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityNCT04962958Written as Donafenib
- A Phase 1/2 Study of Donafenib in Combination With KN046 in Advanced Gastrointestinal TumorsTerminatedPhase 1/2Suzhou Zelgen Biopharmaceuticals Co.,LtdNCT04612712Written as Donafenib Tosilate Tablets
- HAIC Combined With Donafenib and Sintilimab for Unresectable ICCCompletedPhase 2Zhongda HospitalNCT05348811Written as HAIC combined with donafenib and sintilimab
- Donafenib Plus Sintilimab for Advanced HCCCompletedPhase 2Second Affiliated Hospital of Guangzhou Medical UniversityNCT05162352Written as Donafenib+sintilimab
- A Single Center Study of Donafenib Combined With PD-1 + TACE in the First-line Treatment of aHCCCompletedPhase 2Shanghai Zhongshan HospitalNCT05262959Written as Donafenib, PD-1
See all 43 studies that test donafenib →
Given beside what is tested · 4 — donafenib is usual care or a partner of the new treatment
- Dapagliflozin Add-on in Unresectable HCC With Metabolic SyndromeNot yet recruitingPhase 2Sun Yat-sen UniversityNCT07729592Written as Donafenib
- Neoadjuvant HAIC of TACE Plus Donafenib in BCLC B Stage HCC: a Multi-center Randomized Controlled Trial.TerminatedPhase 2/3Peking UniversityNCT05171166Written as Donafenib
- Donafenib and Toripalimab Combined With TACE in Patients With Unresectable Hepatocellular CarcinomaActive, not recruitingPhase 1Suzhou Zelgen Biopharmaceuticals Co.,LtdNCT04605185Written as Donafenib Tosilate Tablets
- A Study of CS1001 in Combination With Donafenib in Subjects With Advanced Solid TumorsStatus unknownPhase 1Suzhou Zelgen Biopharmaceuticals Co.,LtdNCT04472858Written as Donafenib
What changed recently
From the registry's own updates since Oct 20, 2026.
Started recruiting1
Codes
What other systems call donafenib · ClinicalTrials.gg INT001410
- MeSH (NLM) C000710249donafenibConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) 41XGO0VS1UDONAFENIBConfirmed FDA, NLM, Wikidata
- Wikidata Q27258473donafenibConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C118294DonafenibOne source FDA
- DrugBank DB15414One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000710249 | donafenib | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | 41XGO0VS1U | DONAFENIB | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q27258473 | donafenib | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C118294 | Donafenib | One source FDA |
| DrugBank | DB15414 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.